All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

dasiglucagon 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
glucagon-like peptide (GLP) analogues and agonists	5447	1544300-84-6

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: dasiglucagon dasiglucagon hydrochloride zegalogue ZP4207

Dasiglucagon is a glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an antihypoglycemic effect. Molecular weight: 3381.66 Formula: C152H222N38O50 CLOGP: LIPINSKI: 3 HAC: 88 HDO: 52 TPSA: 1448.19 ALOGS: -4.74 ROTB: 109

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
March 22, 2021	FDA	ZEALAND PHARMA AS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H04AA02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PANCREATIC HORMONES GLYCOGENOLYTIC HORMONES Glycogenolytic hormones
FDA PE	N0000009345	Increased Glycogenolysis
FDA EPC	N0000190852	Antihypoglycemic Agent
FDA MoA	N0000193923	Glucagon Receptor Agonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypoglycemia due to diabetes mellitus	indication	237633009
Insulinoma	contraindication	302822000	DOID:3892
Pheochromocytoma	contraindication	302835009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	ZEGALOGUE	ZEALAND PHARMA	N214231	March 22, 2021	RX	SOLUTION	SUBCUTANEOUS	March 22, 2026	NEW CHEMICAL ENTITY
EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	ZEGALOGUE (AUTOINJECTOR)	ZEALAND PHARMA	N214231	March 22, 2021	RX	SOLUTION	SUBCUTANEOUS	March 22, 2026	NEW CHEMICAL ENTITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucagon receptor	GPCR	P47871	GLR_HUMAN	AGONIST	EC50	11		DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D11359	KEGG_DRUG
AD4J2O47FQ	UNII
C5139868	UMLSCUI
CHEMBL4297741	ChEMBL_ID
126961379	PUBCHEM_CID
DB15226	DRUGBANK_ID
CHEMBL4650274	ChEMBL_ID
018680	NDDF
018681	NDDF
4040381	VANDF
2535233	RXNORM
39407	MMSL
d09724	MMSL
C000710373	MESH_SUPPLEMENTAL_RECORD_UI
10480	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Zegalogue	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1912	INJECTION, SOLUTION	0.60 mg	SUBCUTANEOUS	NDA	29 sections
Zegalogue	HUMAN PRESCRIPTION DRUG LABEL	1	0169-1913	INJECTION, SOLUTION	0.60 mg	SUBCUTANEOUS	NDA	29 sections
Zegalogue	HUMAN PRESCRIPTION DRUG LABEL	1	80644-0012	INJECTION, SOLUTION	0.60 mg	SUBCUTANEOUS	NDA	30 sections
Zegalogue	HUMAN PRESCRIPTION DRUG LABEL	1	80644-0012	INJECTION, SOLUTION	0.60 mg	SUBCUTANEOUS	NDA	30 sections
Zegalogue	HUMAN PRESCRIPTION DRUG LABEL	1	80644-0012	INJECTION, SOLUTION	0.60 mg	SUBCUTANEOUS	NDA	30 sections
Zegalogue	HUMAN PRESCRIPTION DRUG LABEL	1	80644-0013	INJECTION, SOLUTION	0.60 mg	SUBCUTANEOUS	NDA	30 sections
Zegalogue	HUMAN PRESCRIPTION DRUG LABEL	1	80644-0013	INJECTION, SOLUTION	0.60 mg	SUBCUTANEOUS	NDA	30 sections
Zegalogue	HUMAN PRESCRIPTION DRUG LABEL	1	80644-0013	INJECTION, SOLUTION	0.60 mg	SUBCUTANEOUS	NDA	30 sections